We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $962M
1-Year Est. Return 524.64%
This Fund
S&P 500
This Quarter Est. Return
+60.76%
1 Year Est. Return
+524.64%
3 Year Est. Return
+2,765.44%
5 Year Est. Return
+10,523.08%
10 Year Est. Return
–
AUM
$323M
AUM Growth
+$81M
Cap. Flow
+$40.9M
Cap. Flow %
12.64%
Top 10 Hldgs %
43.73%
Holding
97
New
25
Increased
29
Reduced
18
Closed
15

Top Buys

Rank Stock Value
1
IMGN
Immunogen Inc
IMGN
+$15M
2
MORF
Morphic Holding, Inc. Common Stock
MORF
+$10.5M
3
KRYS icon
Krystal Biotech
KRYS
+$8.67M
4
BIIB icon
Biogen
BIIB
+$4.63M
5
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$4.59M

Top Sells

Rank Stock Value
1
BLU
BELLUS Health Inc.
BLU
+$7.2M
2
NUVL
Nuvalent
NUVL
+$6.29M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$4.11M
4
PHVS icon
Pharvaris
PHVS
+$3.48M
5
KPTI icon
Karyopharm Therapeutics
KPTI
+$2.94M

Sector Composition

Rank Sector Weight
1 Healthcare 91.54%
2 Miscellaneous 8.39%
3 Consumer Staples 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMGN
1
DELISTED
Immunogen Inc
IMGN
$26.8M 8.29%
1,420,000
+1,270,000
+847% +$15M
MRUS
2
DELISTED
Merus
MRUS
$15.5M 4.8%
589,255
-79,529
-12% -$1.74M
MORF
3
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$14.5M 4.47%
252,309
+200,625
+388% +$10.5M
SDGR icon
4
Schrodinger
SDGR
$1.47B
$14.3M 4.42%
286,169
+73,344
+34% +$2.48M
KRYS icon
5
Krystal Biotech
KRYS
$10.4B
$14M 4.32%
118,941
+84,927
+250% +$8.67M
ITCI
6
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$12.6M 3.89%
198,723
+73,688
+59% +$4.59M
AKRO
7
DELISTED
Akero Therapeutics
AKRO
$11.3M 3.49%
241,357
+38,796
+19% +$1.78M
ORIC icon
8
Oric Pharmaceuticals
ORIC
$1.37B
$11.3M 3.48%
1,450,822
+14,877
+1% +$84.5K
AKRO
9
CALL
DELISTED
Akero Therapeutics
AKRO
$11M 3.42%
+236,500
New +$10.8M
MLTX icon
10
MoonLake Immunotherapeutics
MLTX
$1.28B
$10.2M 3.16%
200,000
+94,250
+89% +$2.54M
BIIB icon
11
Biogen
BIIB
$32.3B
$7.65M 2.37%
26,854
+15,543
+137% +$4.63M
ETNB
12
DELISTED
89bio
ETNB
$7.51M 2.32%
396,497
-41,718
-10% -$733K
COGT icon
13
Cogent Biosciences
COGT
$6.02B
$7.34M 2.27%
620,000
+40,736
+7% +$467K
ACRS icon
14
CALL
Aclaris Therapeutics
ACRS
$885M
$6.76M 2.09%
651,400
– –
UTHR icon
15
United Therapeutics
UTHR
$22.1B
$6.63M 2.05%
30,029
+11,451
+62% +$2.54M
MGNX icon
16
MacroGenics
MGNX
$263M
$6.5M 2.01%
1,215,675
-146,134
-11% -$901K
KALV
17
DELISTED
KalVista Pharmaceuticals
KALV
$6.48M 2.01%
720,508
-3,036
-0.4% -$28K
VCYT icon
18
Veracyte
VCYT
$3.48B
$5.84M 1.81%
229,451
+19,798
+9% +$480K
MRTX
19
CALL
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$5.42M 1.68%
+150,000
New +$6.18M
BCRX icon
20
BioCryst Pharmaceuticals
BCRX
$2.51B
$5.36M 1.66%
760,904
+183,147
+32% +$1.47M
TERN
21
DELISTED
Terns Pharmaceuticals
TERN
$5.25M 1.62%
599,668
-68,254
-10% -$796K
PSTX
22
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$5.18M 1.6%
2,945,948
+256,647
+10% +$656K
NUVL
23
DELISTED
Nuvalent
NUVL
$4.85M 1.5%
115,067
-166,466
-59% -$6.29M
GILD icon
24
Gilead Sciences
GILD
$181B
$4.66M 1.44%
60,448
+318
+0.5% +$25.4K
VRTX icon
25
Vertex Pharmaceuticals
VRTX
$137B
$4.64M 1.43%
13,175
-6
-0% -$2.02K
1
2 3 4

Similar funds

LGP
Leonard Green & Partners Los Angeles, California $962M AUM 35.11% 1-Year Est. Return
PL
Parthenon LLC Louisville, Kentucky $962M AUM 27.46% 1-Year Est. Return
LAM
L2 Asset Management Wayland, Massachusetts $963M AUM 38.06% 1-Year Est. Return
ACP
Aviance Capital Partners Naples, Florida $963M AUM 32.56% 1-Year Est. Return
GIG
Goodnow Investment Group Darien, Connecticut $964M AUM 2.51% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
BEAM
Baker Ellis Asset Management Vancouver, Washington $964M AUM 39.24% 1-Year Est. Return
RAM
Ramirez Asset Management New York $960M AUM 30.25% 1-Year Est. Return

Silverarc Capital Management's Q2 2023 Portfolio in Review

As of Q2 2023, Silverarc Capital Management held 97 positions worth $323M, up 33% from $242M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Silverarc Capital Management deployed $40.9M of net new capital in Q2 2023, opening 25 new positions and adding to 29 existing holdings. Its largest new stake was Mirati Therapeutics, Inc. Common Stock: 91,213 shares worth $3.3M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 92% a quarter earlier, followed by Miscellaneous and Consumer Staples.

On the sell side, the largest reduction was Nuvalent, an estimated $6.29M trimmed.

  • Silverarc Capital Management's largest Q2 2023 buy was Mirati Therapeutics, Inc. Common Stock: 91,213 shares worth $3.3M.
  • Silverarc Capital Management added most to Immunogen Inc in Q2 2023, an estimated $15M increase.
  • Silverarc Capital Management's biggest Q2 2023 reduction was Nuvalent, cutting an estimated $6.29M.
  • Silverarc Capital Management fully exited BELLUS Health Inc. in Q2 2023, selling an estimated $7.2M.
  • Silverarc Capital Management's ten largest holdings make up 44% of its $323M portfolio in Q2 2023.
  • Silverarc Capital Management opened 25 new positions and closed 15 in Q2 2023.
  • Silverarc Capital Management's portfolio value rose 33% quarter-over-quarter to $323M.

Based on Silverarc Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.